Royal Bank of Canada’s Kezar Life Sciences KZR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-322
| Closed | -$2K | – | 7594 |
|
|
2026
Q1 | $2K | Buy |
322
+210
| +188% | +$1.37K | ﹤0.01% | 6712 |
|
|
2025
Q4 | $1K | Buy |
+112
| New | +$653 | ﹤0.01% | 7007 |
|
|
2024
Q3 | – | Sell |
-346
| Closed | -$2K | – | 7154 |
|
|
2024
Q2 | $2K | Buy |
346
+183
| +112% | +$1.39K | ﹤0.01% | 6736 |
|
|
2024
Q1 | $1K | Sell |
163
-2,079
| -93% | -$18.9K | ﹤0.01% | 6810 |
|
|
2023
Q4 | $21K | Buy |
2,242
+1,044
| +87% | +$9.18K | ﹤0.01% | 6294 |
|
|
2023
Q3 | $14K | Buy |
1,198
+452
| +61% | +$8.01K | ﹤0.01% | 6310 |
|
|
2023
Q2 | $18K | Buy |
746
+447
| +149% | +$11.6K | ﹤0.01% | 6266 |
|
|
2023
Q1 | $9K | Sell |
299
-498
| -62% | -$28.8K | ﹤0.01% | 6367 |
|
|
2022
Q4 | $56K | Buy |
797
+719
| +922% | +$53.3K | ﹤0.01% | 5809 |
|
|
2022
Q3 | $7K | Buy |
78
+50
| +179% | +$4.86K | ﹤0.01% | 6595 |
|
|
2022
Q2 | $2K | Sell |
28
-205
| -88% | -$18.1K | ﹤0.01% | 6963 |
|
|
2022
Q1 | $39K | Sell |
233
-377
| -62% | -$54.1K | ﹤0.01% | 6251 |
|
|
2021
Q4 | $102K | Buy |
610
+215
| +54% | +$24.3K | ﹤0.01% | 5918 |
|
|
2021
Q3 | $34K | Buy |
395
+161
| +69% | +$10.7K | ﹤0.01% | 6384 |
|
|
2021
Q2 | $13K | Sell |
234
-15
| -6% | -$852 | ﹤0.01% | 6773 |
|
|
2021
Q1 | $15K | Buy |
249
+102
| +69% | +$5.96K | ﹤0.01% | 6599 |
|
|
2020
Q4 | $8K | Buy |
+147
| New | +$8.18K | ﹤0.01% | 6480 |
|
|
2020
Q3 | – | Sell |
-5
| Closed | – | – | 6790 |
|
|
2020
Q2 | $0 | Sell |
5
-10
| -67% | -$505 | ﹤0.01% | 6767 |
|
|
2020
Q1 | $1K | Sell |
15
-103
| -87% | -$4.19K | ﹤0.01% | 6452 |
|
|
2019
Q4 | $5K | Buy |
+118
| New | +$3.63K | ﹤0.01% | 6357 |
|
|
2018
Q4 | – | Sell |
-22
| Closed | -$5K | – | 6940 |
|
|
2018
Q3 | $5K | Buy |
+22
| New | +$3.84K | ﹤0.01% | 6263 |
|
Royal Bank of Canada's KZR Position: Q2 2026 in Review
Royal Bank of Canada sold out of Kezar Life Sciences (KZR) in Q2 2026, closing a stake of 322 shares — an estimated $2K sold.
Royal Bank of Canada first reported a position in KZR in Q3 2018 and held it in 21 quarters. The position peaked at $102K in Q4 2021. 0 funds tracked by Wall St. Rank hold KZR as of Q2 2026.
- Royal Bank of Canada reported no remaining Kezar Life Sciences position as of Q2 2026 after selling out during the quarter.
- Royal Bank of Canada sold 322 Kezar Life Sciences shares in Q2 2026, an estimated $2K.
- Royal Bank of Canada first reported a position in Kezar Life Sciences in Q3 2018 and held it in 21 quarters.
- Royal Bank of Canada's Kezar Life Sciences position peaked at $102K in Q4 2021.
- 0 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2026.
Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.